ISTA Pharmaceuticals rated hold by Jefferies

ISTA Pharmaceuticals Inc. was rated hold with an $8.75 price target by Jefferies & Co., Inc. analysts David H. Windley and Himanshu Rastogi. They noted the company's newest launch, Xibrom, must improve its growth to meet Jefferies' forecast. ISTA shares closed Thursday down $0.20, or 2.48%, at $7.85 on volume of 103,502 shares versus a three-month trailing average of 182,808 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.